Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
Olfactory Function and Model-based Behavior in People Living With HIV and SUD
Background:
Human immunodeficiency virus (HIV) infection can affect areas of the brain that control thinking ability. These same areas of the brain also control the sense of smell. HIV infection is common in people with substance use disorder (SUD). SUD also affects thinking ability. Researchers want to learn more about the connection between the sense of smell and decision-making ability in people with HIV, SUD, or both.
Objective:
To test the sense of smell in people with HIV and/or SUD and how they make choices based on odors.
Eligibility:
People aged 18 to 65 years with any of these: (1) HIV, (2) SUD, (3) both HIV and SUD, or (4) neither SUD nor HIV.
Design:
Participants will have 2 visits. Each visit will last 3 to 5 hours.
In visit 1, participants will have a blood draw and a saliva swab. They will answer questions about their health, sleep habits, food intake, and substance use. They will have smell tests:
They will smell scented sticks and answer questions about them. They will be blindfolded for some tests.
They will perform tasks on a computer. They will look at pictures and smell pleasant food odors, such as chocolate cake or pizza. Smells will be delivered using a nasal mask. Their sniffing and breathing will be measured. They may also be exposed to odor-free air. They will eat food that corresponds to one of the food odors they smelled.
In visit 2, participants will do a saliva swab and a different computer task that involves odors. They will also have tests of their attention and memory. Participants may opt to have an imaging scan of the brain.
調査の概要
詳細な説明
Study Description:
Cognitive impairments persist in people living with Human Immunodeficiency Virus (HIV) despite anti-retroviral therapy (ART). However, these impairments remain under-characterized and it is not clear whether they include deficits in model-based control of behavior. HIV is common in people with substance use disorder (SUD) but the combined impact of HIV and SUD on cognition remains unclear. The olfactory system is uniquely vulnerable to neurodegeneration and overlaps with brain regions involved in decision making. This study will investigate olfactory function and model-based behavior in people living with HIV and SUD, and relate these measures to biomarkers of neurodegeneration.
Objectives:
The primary objective of this protocol is to compare olfactory function and performance on behavioral tasks assessing model-based behavior between people living with and without HIV, and between people with and without SUD.
Secondary objectives of this protocol are to compare blood-based and MRI0-based biomarkers of neurodegeneration between people living with and without HIV, and between people with and without SUD.
Endpoints:
Primary:
- Olfactory function (Sniffin Sticks Threshold, Discrimination, and Identification tests)
- Behavior on tasks assessing model-based behavior (outcome devaluation and sensory preconditioning)
Secondary:
- Blood-based biomarker of neurodegeneration (Neurofilament Light Chain [NfL])
- MRI-based biomarker of neurodegeneration (Magnetic Resonance Imaging)
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:NIDA IRP Screening Team
- 電話番号:(800) 535-8254
- メール:researchstudies@nida.nih.gov
研究連絡先のバックアップ
- 名前:Thorsten Kahnt, Ph.D.
- 電話番号:(667) 312-5175
- メール:thorsten.kahnt@nih.gov
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21224
- National Institute on Drug Abuse
-
コンタクト:
- Thorsten Kahnt
- 電話番号:667-312-5175
- メール:thorsten.kahnt@nih.gov
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
For all participants:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Aged 18-65 years old. Justification: prevalence of olfactory impairments increases with age; after age 53, the prevalence is 24.5 percent, increasing to 62.5 percent in people ages 80-97.
- Agreement to adhere to Lifestyle Considerations throughout study duration.
- Ability of subject to understand and the willingness to sign a written informed consent document.
For participants in the HIV+ and SUD+ and HIV+ and SUD- groups:
-HIV positive.
For participants in the HIV+ and SUD+ and HIV- & SUD+ groups:
-Substance Use Disorder (SUD) other than Alcohol Use Disorder (AUD) or Tobacco Use Disorder (TUD).
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
For all participants:
- History of neurological illnesses or neurosurgery including but not limited to cerebrovascular accident, Parkinson disease, Alzheimer disease, Huntington disease, central nervous system (CNS) tumor, significant head trauma with sequelae, multiple sclerosis or other demyelinating diseases, epilepsy, movement disorders. The MAI will also retain discretion to exclude based on a history of a neurological illness or trauma that may compromise data integrity.
- History of current (past 12 months) uncontrolled major DSM-5 psychiatric disorder including major affective disorder, obsessive-compulsive disorder, schizophrenia, or posttraumatic stress disorder, excluding SUD.
- Candidates who recently (12 hours prior to a study visit) used medications and/or substances that are psychoactive or otherwise affect alertness will have to pass a clinical assessment for intoxication on the day of the study visit. Based on participant preferences and MAI/PI judgment, participants who fail the clinical assessment for intoxication will either be withdrawn or rescheduled.
- History of clinically significant anaphylaxis, e.g., due to severe asthma or food and nonfood allergies (e.g., latex, detergents, soap, etc.). The MAI will retain discretion to exclude a participant based on this criterion.
- Uncorrected impairments in visual acuity.
- Non-English speaking. Justification: The data integrity of some of the behavioral tasks used in this study would be compromised as they have only been validated in English.
- Pregnancy.
- Any other condition that in the judgment of the investigators is incompatible with participation.
For participants in the HIV+ and SUD- and HIV- and SUD- groups:
- History of current (past 12 months) SUD, excluding tobacco use disorder.
- Pattern of alcohol and drug use in the past 12 months that is indicative of harmful use, loss of control over use, or physical dependence.
- Daily alcohol or drug use (excluding caffeine and nicotine) for at least 4 continuous weeks in the past 12 months.
For participants in the HIV- and SU+ and HIV- and SUD- groups:
-HIV positive.
For the Optional MRI Segment:
-Unable to undergo MRI scanning due to certain metallic or magnetic devices or implants in the body, or claustrophobia.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
HIV- & SUD-
Individuals without HIV and without an SUD
|
|
HIV- & SUD+
Individuals without HIV and with an SUD
|
|
HIV+ & SUD-
Individuals with HIV and without an SUD
|
|
HIV+ & SUD+
Individuals with HIV and with an SUD
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Olfactory function
時間枠:Visit 1
|
Sniffin Sticks Threshold, Discrimination, and Identification tests
|
Visit 1
|
|
Model-based decision making
時間枠:Visit 1 & 2
|
Model-based decision making as assessed in an outcome devaluation task (visit 1) and sensory preconditioning task (visit 2)
|
Visit 1 & 2
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Neurofilament Light Chain
時間枠:Visit 1
|
Plasma levels of neurofilament light chain [NfL]
|
Visit 1
|
|
MRI
時間枠:Visit 2 (optional)
|
MRI-based biomarkers of neurodegeneration
|
Visit 2 (optional)
|
協力者と研究者
捜査官
- 主任研究者:Thorsten Kahnt, Ph.D.、National Institute on Drug Abuse (NIDA)
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 10002591
- 002591-DA
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD 共有時間枠
IPD 共有アクセス基準
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。